Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Retatrutide for Sale > Retatrutide GIPR/GLP-1R/GCGR, CAS 2381089-83-2
Retatrutide GIPR/GLP-1R/GCGR, CAS 2381089-83-2 buy - large image1
Retatrutide GIPR/GLP-1R/GCGR, CAS 2381089-83-2 buy - image1

Retatrutide GIPR/GLP-1R/GCGR, CAS 2381089-83-2

6854 Inquiries

Unit Price: Get Latest Price
CAS No.:

2381089-83-2

Grade:

Industrial Grade

Content:

99.99%

Port:

Shanghai

Brand:

Honour

Packaging:

Any pacakge is available

Price valid (until):

2023-11-26

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Semaglutide,Tirzepatide,API,Enzyme

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


    Product nameRetatrutide GIPR/GLP-1R/GCGR,
    CAS Num.2381089-83-2
    Purity99.99%
    Appearance White powder
    COA, MSDSRetatrutide GIPR/GLP-1R/GCGR COA is available


      Product Detail  






    Sample & Customization

    1. We offer sample for test.

    2. Customization service is available




    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    Molecular Formula:

    C221H342N46O68

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    4731.33

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Semaglutide,Tirzepatide,API,Enzyme

    Location:

    Unit ST-308, No. 329, Jiahe Road, Siming District, Xiamen

    Payment Terms:

    TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    7

    Total Annual Revenue:

    $50 million-$100 million

    Total Employees:

    11-50

    Year of Establishment:

    2018

    Honour Enterprise Company Limited, found in 2008, specialized in R&D, manufacture and export various of fine chemicals. We are one of the leading export corporation in China.We have enjoyed good reputation in the world market for a long time,because of the competitive price, excellent quality, delivery immediate on time, we are received the extensive favorable comment of the foreign customer deeply.  R&D Center One of the benefits of the long-term relationships we develop with our clients is in the new product development area,our products are well sold in America, Europe,Japan, Singapore, South Korea.


    AfteAfter years of development, our company has accumulated abundant products resources in local China and international market which increasingly satisfy development requirements of customers. The products includes fine chemicals, food additives, feed additives, Pharmaceutical intermediates, pesticides, dyes and pharmaceutical and monomer for contact lens material custom synthesis is also available.


    Our vision is to supply our customers with the highest quality ingredients with competitive price and excellent service through our professional knowledge. We will achieve our vision by working closely with our partners from all over the world.


     

  • Inquiry History
    6854 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Retatrutide 2381089-83-2

    3 MT Mar 28, 2026
    United Kingdom

    Retatrutide - 2381089-83-2

    1 G Feb 10, 2026
    United States

    Retatrutide CAS 2381089-83-2 10mg vial

    20 MT Mar 7, 2026
    United States

    Factory Retatrutide API 99% Purity CAS 2381089-83-2

    5 KG Nov 10, 2025
    United Kingdom

    Peptide powder Retatrutide 99% pure for Body building cas 2381089-83-2 Weight Loss Peptide with COA

    1 MT Mar 22, 2026
    United States

    2381089-83-2

    100 G Jul 14, 2026
    United States

    2381089-83-2

    100 G Feb 24, 2026
    United States

    2381089-83-2

    100 MT Dec 9, 2023
    United States

    Retatrutide 2381089-83-2

    200 MG May 16, 2026
    United Kingdom

    2381089-83-2 retatrutide

    300 MG Feb 13, 2026
    United States

    Retatrutide 2381089-83-2 wholesale

    500 MT Nov 3, 2023
    Poland

    CAS 2381089-83-2 (Custom Peptide)

    40 MT Apr 10, 2026
    Austria

    Peptide Retatruide CAS 2381089-83-2

    100 MT Apr 4, 2026
    United States

    Retatrutide CAS 2381089-83-2 99%

    10 PCS Feb 21, 2026
    Austria

    Retatrutide CAS 2381089-83-2 10mg vial

    20 PCS Feb 10, 2026
    United States

    Tirzepatide 99.9% Liquid 2381089-83-2 TeruiOP

    1 MT Sep 6, 2023
    United States

    GLP-1 / GIP Retatrutide cas 2381089-83-2

    1 MT Oct 16, 2024
    United States

    Retatrutide 99% High Quality CAS 2381089-83-2

    1 G Jan 23, 2026
    United States

    Injection Peptide Tirzepatide/Retatrutide/ Semaglutide Peptides CAS 2381089-83-2

    10  Oct 21, 2023
    Australia

    GMP Grade 99% Retatrutide Lyophilized Powder CAS 2381089-83-2

    10 G Jun 12, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.